Cardiotoxicity of Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients
Open Access
Abstract
In the past twenty years, tyrosine kinase inhibitors (TKIs) have substantially changed the therapeutic landscape and the clinical outcome of several cancers, including Philadelphia-chromosome positive chronic myeloid leukemia and acute lymphoblastic leukemia, chronic eosinophilic syndromes, gastrointestinal stromal tumors, and others. Despite the obvious advantages offered in terms of efficacy and the overall safety profile, this new class of agents presents novel side effects, sometimes different from those induced by conventional chemotherapy. Among others, the potential cardiac toxicity, characterized by possible arrhythmias and the highest rates of cardiac ischemic disease and heart failure, were predominantly investigated. In this article, the authors review the most significant evidence in this regard, highlighting the overall benefit of TKI usage and the need for careful monitoring, especially in elderly patients.Keywords
Funding Information
- BolognAIL
- RFO DIMES
- FIRB Futura 2011 RBFR12D1CB
This publication has 41 references indexed in Scilit:
- Severe Peripheral Arterial Disease During Nilotinib TherapyJNCI: Journal of the National Cancer Institute, 2011
- New dosing schedules of dasatinib for CML and adverse event managementJournal of Hematology & Oncology, 2009
- Cardiotoxicity induced by tyrosine kinase inhibitorsActa Oncologica, 2009
- An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxicJournal of Clinical Investigation, 2007
- Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicityAnnals of Oncology, 2007
- Imatinib mesylate in the treatment of hematologic malignanciesExpert Opinion on Biological Therapy, 2007
- Congestive heart failure is a rare event in patients receiving imatinib therapyBlood, 2007
- Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trialBlood, 2007
- Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005European Journal of Cancer, 2007
- Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C δGenes & Development, 2004